Raymond James Financial
LUCD icon

Raymond James Financial’s Lucid Diagnostics LUCD Stock Holding History

Raymond James Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$434K Hold
577,381
– – ﹤0.01% 4661
2026
Q2 		$618K Buy
577,381
+52,445
+10% +$56.5K ﹤0.01% 4357
2026
Q1 		$604K Buy
+524,936
New +$668K ﹤0.01% 4223
2025
Q3 		– Sell
-791
Closed -$910 – 5969
2025
Q2 		$910 Buy
+791
New +$1.02K ﹤0.01% 6583

Other funds holding LUCD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Perkins Capital Management
Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Raymond James Financial's LUCD Position: Q3 2026 in Review

Raymond James Financial held its Lucid Diagnostics (LUCD) position steady in Q3 2026 at 577,381 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #4661.

Raymond James Financial first reported a position in LUCD in Q2 2025 and has held it in 4 quarters since. The position peaked at $618K in Q2 2026. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Raymond James Financial held 577,381 shares of Lucid Diagnostics worth $434K as of Q3 2026.
  • Raymond James Financial left its Lucid Diagnostics share count unchanged in Q3 2026.
  • Lucid Diagnostics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4661 holding.
  • Raymond James Financial first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Lucid Diagnostics position peaked at $618K in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.